CY1112329T1 - Συστηματα και μεθοδοι για διανοιξη αποφραγμενων βιολογικων αγωγων - Google Patents

Συστηματα και μεθοδοι για διανοιξη αποφραγμενων βιολογικων αγωγων

Info

Publication number
CY1112329T1
CY1112329T1 CY20111100865T CY111100865T CY1112329T1 CY 1112329 T1 CY1112329 T1 CY 1112329T1 CY 20111100865 T CY20111100865 T CY 20111100865T CY 111100865 T CY111100865 T CY 111100865T CY 1112329 T1 CY1112329 T1 CY 1112329T1
Authority
CY
Cyprus
Prior art keywords
blockage
pipes
systems
methods
conduit
Prior art date
Application number
CY20111100865T
Other languages
English (en)
Inventor
Nicholas F Franano
Original Assignee
Proteon Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteon Therapeutics, Inc. filed Critical Proteon Therapeutics, Inc.
Publication of CY1112329T1 publication Critical patent/CY1112329T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processing Of Meat And Fish (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

Η εφεύρεση παρέχει μεθόδους για θεραπεία αποφραγμένου βιολογικού αγωγού που περιλαμβάνει χορήγηση στον αγωγό ενός παράγοντα που μπορεί να αποικοδομήσει εξωκυτταρική μήτρα αποφραχθέντος ιστού. Συγκεκριμένες μέθοδοι περιλαμβάνουν απελευθέρωση ενός ενζύμου ή μίγματος διαφόρων ενζύμων στην περιοχή ή στο τμήμα της απόφραξης όπου το ένζυμο(-α) έχει την ικανότητα να αποικοδομεί συστατικά εξωκυτταρικής μήτρας εντός της απόφραξης αποκαθιστώντας με τον τρόπο αυτό την κανονική ροή μεταφερόμενου ρευστού διαμέσου του αγωγού. Η εφεύρεση επίσης περιλαμβάνει προληπτικώς διάταση ενός τμήματος του αγωγού για να ελαχιστοποιείται ο κίνδυνος σχηματισμού απόφραξης.
CY20111100865T 1999-09-24 2011-09-08 Συστηματα και μεθοδοι για διανοιξη αποφραγμενων βιολογικων αγωγων CY1112329T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15593899P 1999-09-24 1999-09-24
EP20070008805 EP1923068B1 (en) 1999-09-24 2000-09-24 Systems and methods for opening obstructed biological conduits

Publications (1)

Publication Number Publication Date
CY1112329T1 true CY1112329T1 (el) 2015-12-09

Family

ID=22557384

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20071100790T CY1106656T1 (el) 1999-09-24 2007-06-14 Χρηση ελαστασης για διανοιξη αποφραγμενων αρτηριων και φλεβων
CY20111100865T CY1112329T1 (el) 1999-09-24 2011-09-08 Συστηματα και μεθοδοι για διανοιξη αποφραγμενων βιολογικων αγωγων
CY20151100477T CY1117932T1 (el) 1999-09-24 2015-05-29 Ελασταση για διανοιξη αποφραγμενων βιολογικων διαυλων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20071100790T CY1106656T1 (el) 1999-09-24 2007-06-14 Χρηση ελαστασης για διανοιξη αποφραγμενων αρτηριων και φλεβων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20151100477T CY1117932T1 (el) 1999-09-24 2015-05-29 Ελασταση για διανοιξη αποφραγμενων βιολογικων διαυλων

Country Status (12)

Country Link
EP (4) EP2363142B8 (el)
JP (2) JP5763286B2 (el)
AT (2) ATE361095T1 (el)
AU (1) AU7612100A (el)
CA (1) CA2385488C (el)
CY (3) CY1106656T1 (el)
DE (1) DE60034694T2 (el)
DK (3) DK2363142T3 (el)
ES (3) ES2284528T3 (el)
HK (1) HK1162302A1 (el)
PT (3) PT1220830E (el)
WO (1) WO2001021574A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063838B1 (en) 1999-09-24 2006-06-20 Proteon Therapeutics Llc Methods for treating an artery or vein in a human subject
JP2007525423A (ja) * 2003-02-20 2007-09-06 プロテオン セラピューティクス，インコーポレーテッド 生体導管の疾患を治療および予防するための方法
US20090196865A1 (en) * 2004-09-22 2009-08-06 Proteon Therapeutics, Inc. Methods for the treatment and prevention of diseases of biological conduits
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
DK2802652T3 (da) 2012-01-12 2019-07-15 Endo Global Ventures Clostridium histolyticum enzym
WO2014066622A2 (en) 2012-10-24 2014-05-01 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
JP7558654B2 (ja) 2017-03-01 2024-10-01 エンド ベンチャーズ アンリミテッド カンパニー セルライトを評価及び処置するための装置及び方法
KR20240001279A (ko) 2017-03-28 2024-01-03 엔도 벤쳐즈 리미티드 개선된 콜라게나제 생성 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489261A (en) * 1981-01-26 1996-02-06 Trustees Of Boston University Hydrogels capable of supporting cell growth
US4636195A (en) * 1982-04-02 1987-01-13 Harvey Wolinsky Method and apparatus for removing arterial constriction
US4803294A (en) * 1987-10-29 1989-02-07 G. D. Searle & Co. Process and intermediates for the preparation of halogenated protease inhibitors
JPH0286777A (ja) * 1988-09-22 1990-03-27 Sankyo Co Ltd サル膵臓エラスターゼｉ
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
AU5045690A (en) * 1989-01-27 1990-08-24 Immunolytics, Inc. Composition and method for treating benign prostatic hypertrophy
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
NL8900943A (nl) * 1989-04-14 1990-11-01 Euro Biopharm Technology B V Protease inhibitor.
US5318531A (en) * 1991-06-11 1994-06-07 Cordis Corporation Infusion balloon catheter
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5422261A (en) * 1993-04-16 1995-06-06 Baxter International Inc. Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells
US5409926A (en) 1993-07-19 1995-04-25 Merck & Co., Inc. AT-2 antagonist inhibition of vascular restenosis
ATE354638T1 (de) * 1994-12-13 2007-03-15 Human Genome Sciences Inc Menschlicher gewebsinhibitor von metalloproteinase-4
US5830468A (en) * 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US6020181A (en) * 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5834449A (en) * 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors

Also Published As

Publication number Publication date
EP2363142A1 (en) 2011-09-07
HK1162302A1 (en) 2012-08-31
PT1220830E (pt) 2007-06-11
EP1923068B1 (en) 2011-06-08
PT2363142E (pt) 2015-08-04
PT1923068E (pt) 2011-07-29
EP1923068A1 (en) 2008-05-21
CA2385488C (en) 2015-07-07
JP2012131830A (ja) 2012-07-12
ATE361095T1 (de) 2007-05-15
JP5763286B2 (ja) 2015-08-12
AU7612100A (en) 2001-04-24
CA2385488A1 (en) 2001-03-29
EP1220830A4 (en) 2005-03-30
DK2363142T3 (en) 2015-04-20
EP1220830B1 (en) 2007-05-02
EP2363142A9 (en) 2011-10-19
ES2534938T3 (es) 2015-04-30
EP2363142B8 (en) 2015-06-10
CY1106656T1 (el) 2012-01-25
CY1117932T1 (el) 2017-05-17
ES2284528T3 (es) 2007-11-16
EP2332568A1 (en) 2011-06-15
DK1923068T3 (da) 2011-06-27
EP1220830A1 (en) 2002-07-10
WO2001021574A1 (en) 2001-03-29
WO2001021574A9 (en) 2002-12-27
DE60034694D1 (de) 2007-06-14
JP5793461B2 (ja) 2015-10-14
DE60034694T2 (de) 2008-01-17
ATE511854T1 (de) 2011-06-15
DK1220830T3 (da) 2007-07-16
JP2003523319A (ja) 2003-08-05
ES2364191T3 (es) 2011-08-26
EP2363142B1 (en) 2015-03-25

Similar Documents

Publication Publication Date Title
CY1112329T1 (el) Συστηματα και μεθοδοι για διανοιξη αποφραγμενων βιολογικων αγωγων
ES2130423T3 (es) Sistema de administracion intravaginal.
BR9606428A (pt) Dispositivo processo para desinfectar uma área dispositivo médico sistema para acoplar juntas duas vias de fluxo e processo para realizar diálise peritoneal
BRPI0413790A (pt) sistema sem fio, método sem fio, dispositivo de sistema sem fio, dispositivo de usuário sem fio e métodos de operar um dispositivo de sistema sem fio e um dispositivo de usuário sem fio
BR9307011A (pt) Membro de vedação
ES2085781T3 (es) Sistema y procedimiento para el reencamisado de tramos de tuberias de canales.
ATE431166T1 (de) System zum transfer von flüssigkeit im innenohr und zur diagnose
BR0206699A (pt) Sistema de fornecimento de enxerto
ES2050070B1 (es) Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica.
AR016217A1 (es) Composicion farmaceutica que comprende un modulador dispositivo de un agonista receptor nicotinico, metodo para el tratamiento de un trastorno asociado conuna transmision reducida de nicotina, metodo para identificar un agonista repector nicotinico, uso de un modulador positivo de un agonista recept
MXPA05003878A (es) Equipos procesadores de fluido y organizadores para lo mismo.
SE9801287D0 (sv) Incorporation of active substances in carrier matrixes
DE60026886D1 (de) System zum einbringen eines harnröhrenstents
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
BR0215389A (pt) Agente preventivo ou terapêutico para distúrbio urinário, método para prevenir ou tratar distúrbio urinário, uso de um composto, composto, pró-droga, processo para preparar o composto, medicamento, e, método para triar um composto
AR015586A1 (es) Composicion farmaceutica de residencia gastrica.
ATE224684T1 (de) Vorrichtung zur geruchskontrolle
ATE223263T1 (de) Vorrichtung und verfahren zur druckwechselspülung
DE59409704D1 (de) In den menschlichen körper einführbares instrument
DE60324019D1 (de) On-wachstumshemmende verbindungen
ES2141923T3 (es) Uso hipocolesterolemico, antiaterosclerotico e hipotrigliceridemico de derivados aminoacetilmercapto.
DK1343387T3 (da) Dekontaminering af dyrefoder indeholdende prion (fx BSE-agens)
SE9703966D0 (sv) Kopplingsdon